Lawyer accuses J&J of negligence in Topamax case; FDA pulls another Wellbutrin generic on lack of bioequivalence;

@FiercePharma: Top news online yesterday: J&J hikes earnings forecast on pharma's superhero sales flight. Story | Follow @FiercePharma

@EricPFierce: MHRA says it also took action against Wockhardt contractor Nestor in U.K. as part of recent action. Article from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Look out, Vivus--Eisai to double Belviq sales force by December 2013. Release | Follow @CarlyHFierce

> Johnson & Johnson ($JNJ) was negligent in warning expectant mothers of the risk of birth defects with its seizure drug Topamax, a lawyer for one woman said, as a trial over her son's cleft palate began. Report

> The FDA said another generic version of Wellbutrin XL, this one from Actavis ($ACT), would be pulled off the market because it is not bioequivalent to the branded drug. Report

> Health Canada said it will better communicate the risks of recalled drugs after a report criticized its handling of Apotex's recall of its birth control pill Alysena 28. Report

> The U.S. Supreme Court declined to hear the case of a woman who sought to hold Hospira ($HSP) liable for a shortage of its injectable drug Aquasol A. Report

> Russia's pharmaceuticals sales are expected to grow by 11% this year, to $130.4 billion, the market research firm Business Monitor says. Report

> Florida prison officials executed a man using the sedative midazolam hydrochloride as part of a three-drug cocktail; the drug had not been used in previous executions. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: FierceMedicalDevices' 2013 Fierce 15. Feature | Follow @FierceMedDev

> TB Dx maker Oxford Immunotec to pursue IPO path. Report

> Myriad vs. Quest over BRCA testing: It's getting serious. More

> Abbott posts med tech growth thanks to diagnostics, dealmaking. Story

Biotech News

@FierceBiotech: ICYMI yesterday: The top Phase III R&D setbacks of 2013. Feature | Follow @FierceBiotech

@JohnCFierce: Third Rock startup banks $20M to fuel next leg of CNS drug development journey. News | Follow @JohnCFierce

@DamianFierce: St. Jude boosts profits as job cuts, M&A pay off. Article | Follow @DamianFierce

@EmilyMFierce: Georgetown University Medical Center researchers find a vegetable-based compound that protects against side effects of radiation therapy. Article from FierceBiotech Research | Follow @EmilyMFierce

> Is Eli Lilly about to start cutting its blockbuster R&D budget? More

> MedImmune leads $12.5M round for new drug aimed at big chemo market. Article

> Sanofi, Regeneron take the lead in blockbuster PhIII race of PCSK9 drugs. Story

Biomarkers News

> Biomarker differentiates ADHD subtypes, offers clues for treatment. Article

> Amgen taps KineMed for Alzheimer's biomarkers. Report

> Skin may conceal a viable Parkinson's biomarker. Story

Drug Delivery News

@MichaelGFierce: AstraZeneca teams with Taris to research bladder cancer delivery device. Story | Follow @MichaelGFierce

> Mini-pancreas grown from stem cells has implications for future insulin delivery. More

> Cell membrane models 'written' on graphene provide drug-delivery model. Item

> Study: Synthetic RNA conjugates target, silence bacteria's genetic material. Article

> Nanoparticle hydrogel heats up to release drugs in active cartilage. Story

Diagnostics News

@MarkHFierce: Smith & Nephew will handle U.S. distribution of a women's care diagnostic device developed by Femasys. Story | Follow @MarkHFierce

> Applied Proteomics to develop pancreatic and colon cancer Dx with German research institute. More

> Quest preemptively sues Myriad to ensure new BRCA test avoids patent violation. Report

> CardioDx's proposed $86.2M IPO will aid marketing and insurance coverage efforts. Story

> New blood test screens for irritable bowel syndrome. Article

> Mount Sinai's Icahn School of Medicine jumps into Dx, drug development. Item

And Finally... U.S. regulators are set to consider whether a "three-parent" reproductive technique should be tested as a way to keep genetic defects from passing from mothers to children. Report